OCTOBER 27–30, 2011 Comprehensive and Coordinated Care: Bringing it all Back Home 2011 PROGRAM 63rd Co-sponsorsed with Drexel University College of Medicine/ Sponsored by Behavioral Healthcare Education APA’s Leading Educational Conference on Public, Community, and Clinical Psychiatry American Psychiatric Associa tion AMR E ICAN PSYCHIATRIC ASSOCIATION 63RD INSTITUTE ON PSYCHIATRIC SERVICES Scientific Program Committee Members: Back Row – Standing Left to Right: Douglas Fraser, Michael J. Yao, M.D., Mary E. Diamond, D.O., M.A., M.P.A., Donna N. McNelis, Ph.D., David A. Pollack, M.D., Neal Adams, M.D., Hunter McQuistion, M.D. Front Row – Seated Left to Right: Wesley E. Sowers, M.D., (Program Chair), Altha J. Stewart, M.D. Not Pictured: Stephanie LeMelle, M.D., Anita S. Everett, M.D., Stephen M. Goldfinger, M.D., Jennifer Kraker, M.D., M.S., John M. Oldham, M.D. (APA President), James H. Scully, Jr., M.D. (APA Medical Director) 2011 SCIENTIFIC PROGRAM COMMITTEE Wesley E. Sowers, M.D. David A. Pollack, M.D. Altha Stewart, M.D. Chair, Scientific Program Committee Vice Chair, Scientific Program Committee Committee Member Pittsburgh, PA West Linn, OR Memphis, TN Hunter L. McQuistion, M.D. Mary E. Diamond, D.O., M.A., M.P.A. Stephanie LeMelle, M.D. Committee Member Committee Member Committee Member Hastings-on-the-Hudson, NY Harrisburg, PA New York, NY CONSU LTA NTS Anita S. Everett, M.D. Douglas Fraser Neal Adams, M.D. Baltimore, MD Albuquerque, NM Local Arrangements Consultant Berkeley, CA LIAISONS John M. Oldham, M.D. Donna N. McNelis, Ph.D. Jennifer Kraker, M.D., M.S. APA President Liaison, CE Accreditation Public Psychiatry Fellow Houston, TX Philadelphia, PA New York, NY Michael J. Yao, M.D., M.P.H. Stephen M. Goldfinger, M.D. Public Psychiatry Fellow Liaison, Psychiatric Services Journal Portland, OR New York, NY Visit Us at Booth 100 You helped him get through opioid detoxification… NOW YOU CAN HELP HIM PREVENT RELAPSE VIVITROL® (naltrexone for extended-release injectable suspension) 380 mg/vial is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. Opioid-dependent patients, including those being treated for alcohol dependence, must be opioid-free at the time of initial VIVITROL administration. The first and only once-monthly, nonaddictive, nonnarcotic medication approved to prevent relapse to opioid dependence, following opioid detoxification1 WARNING: HEPATOTOXICITY1 WARNINGS AND PRECAUTIONS Naltrexone has the capacity to cause hepatocellular injury ÎÎHepatotoxicity when given in excessive doses. ÎÎInjection site reactions Naltrexone is contraindicated in acute hepatitis or liver ÎÎEosinophilic pneumonia failure, and its use in patients with active liver disease must ÎÎHypersensitivity be carefully considered in light of its hepatotoxic effects. ÎÎUnintended precipitation of opioid withdrawal The margin of separation between the apparently safe dose of ÎÎ Opioid overdose at the end of a dosing interval, after missing naltrexone and the dose causing hepatic injury appears to be a dose and following an attempt to overcome opioid blockade only five-fold or less. VIVITROL does not appear to be a ÎÎDepression and suicidality hepatotoxin at the recommended doses. ÎÎ Intramuscular injections ÎÎ When reversal of VIVITROL blockade is required for pain management Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms ADVERSE REACTIONS of acute hepatitis. Use of VIVITROL should be discontinued in The adverse events seen most frequently in association with the event of symptoms and/or signs of acute hepatitis. VIVITROL therapy for alcohol dependence (ie, those occurring in ≥5% and at least twice as frequently with VIVITROL than CONTRAINDICATIONS placebo) include nausea, vomiting, injection site reactions VIVITROL is contraindicated in: (including induration, pruritus, nodules and swelling), muscle ÎÎPatients with acute hepatitis or liver failure cramps, dizziness or syncope, somnolence or sedation, anorexia, ÎÎPatients receiving opioid analgesics decreased appetite or other appetite disorders. ÎÎPatients with current physiologic opioid dependence ÎÎPatients in acute opioid withdrawal The adverse events seen most frequently in association ÎÎ Any individual who has failed the naloxone challenge test or with VIVITROL therapy in opioid-dependent patients (ie, those has a positive urine screen for opioids occurring in ≥2% and at least twice as frequently with VIVITROL ÎÎ Patients who have previously exhibited hypersensitivity to than placebo) were hepatic enzyme abnormalities, injection site naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose, pain, nasopharyngitis, insomnia and toothache. or any other components of the diluent 1. VIVITROL [full prescribing information]. Waltham, MA: Alkermes, Inc; rev October 2010. PLEASE SEE BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING, ON ADJACENT PAGES. Alkermes® and VIVITROL® are registered trademarks of Alkermes, Inc. ©2011 Alkermes, Inc. All rights reserved VOD 0031 0611 Printed in U.S.A. www.vivitrol.com 5116_APA_IPS_Ad_M1.indd 1 9/12/11 6:29 PM EARN CME APAeducation.org ONLINE CME COURSES • APA Major Depressive Disorder (MDD) Practice Guideline Course - Highlights Latest Research Findings and Clinical Approaches to Treatment - 1 of 8 Online Practice Guideline Courses - Earn up to 8 AMA PRA Category 1 Credits™ • Buprenorphine for O ce Based Treatment of Opiate Dependent Patients - 8 Hour Training Program That Meets CSAT Requirements • And More... • My Transcript: A Useful Tool for Recording Your CME - Record and Store Your CME Credits in One Easy to Access Location ENROLL TODAY! EMPLOYERS & CANDIDATES Connect rough APA JOB BANK • Visit the APA Job Bank booth #202 during the meeting to search the most comprehensive online listing of psychiatric positions. • Use APA Job Bank Conference Connection Tool to connect with prospective employers at IPS. • Ask questions, upload your resume to our database, and post your open positions immediately! Subscribe to PSYCHIATRIC SERVICES A Journal of the American Psychiatric Association APA’s high-ranking mental health policy and services journal will keep you informed in a changing environment. One low price covers your print and online subscription! Each issue covers an array of topics, with a focus on people with serious mental illness: • Evidence-based and best practices: delivering effective services and programs • Recovery-oriented, client-centered care: how systems are being transformed • Racial-ethnic disparities in care: how they arise and how to overcome them • Criminal justice involvement and homelessness: diversion and housing programs • Use of medications: improving adherence, monitoring trends and treatment adequacy • Medicaid changes and health care reform: what they mean for your practice One-Year Prices: I U.S. APA Member: $93 I International Member: $169 I APA Member (Online Only): $51 I U.S. Non-Member price: $125 I International Non-Members: $187 I APA Member-in-Training (Online Only): $37 American Psychiatric Publishing I www.appi.org I Phone: 1-800-368-5777 I 703-907-7322 I Fax: 703-907-1091 I Email: [email protected] Visit the APP bookstore to purchase your subscription. Priority Code AH1146 Introducing Psych Services on Demand Over 150 hours of cutting edge content presented at the 63rd Institute on Psychiatric Services Special offer for meeting attendees! Order during the meeting and pay only $299, that’s a $700 savings off the list price. This offer ends October 30th. Psych Services on Demand provides instant access to key educational sessions including Dr. Alan Schatzberg’s course on Essential Psychopharmacology. Features of Psych Services on Demand include: • Online access within 24 hours • Convenient DVD-ROM to view sessions offline • Mobile streaming on the latest technology including iPad®, iPhone® and Android® platforms • The ability to earn an additional 30+ hours of CME • MP3 downloads for convenient audio on-the-go access To claim your attendee discount, visit our sales booth in Golden Gate Hall, C1. Or go to www.CMEonCall.com/APA/IPS and enter promo code IPS. Residents and Students can secure a special price by visiting our booth during the meeting. 63rd Institute on Psychiatric Services APA’s Leading Educational Conference on Public, Community, and Clinical Psychiatry APA Public Psychiatry Fellowship Formerly APA/Bristol Myers Squibb Fellowship Formerly APA Mead Johnson Fellowship Photo Credit: Bev Lloyd-Roberts Credit: Photo The American Psychiatric Association Public Psychiatry Fellowship Program, founded in 1980, provides experi- ences that will contribute to the professional development of residents who will play future leadership roles within public sector psychiatry and heightens awareness of public psychiatry activities and career opportunities. Since the time it was founded, the fellowship has been awarded to 373 outstanding residents, many of whom are now leaders in the eld. This year marks the 30 year anniversary of the Fellowship. The current fellows are pleased to present their work- shops and symposium on the topics of their choice. Former fellows were also invited to present a special sympo- sium on the past and future of public psychiatry. FRIDAY, OCTOBER 28, 2011 Presenters: Kenneth Thompson, MD, Hunter McQuistion, MD, Wesley Sowers, MD, and Warachal